Actively Recruiting
INDICIA: Evolution of the Initial Distribution Volume of Glucose in Severe Burned Adults
Led by Centre Hospitalier Régional Metz-Thionville · Updated on 2026-03-12
15
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to describe how the initial volume of glucose distribution (IDVG) changes during the first four days of treatment in adults with severe burns. Severe burns cause a state of low blood volume shock due to inflammation and capillary leak, leading to fluid buildup outside blood vessels. The study focuses on understanding these fluid volume changes to help improve fluid management in burn patients. Participants will receive intravenous glucose to measure the IDVG at various times: on admission, and at 4, 8, 16, 24, 48, 72, and 96 hours after the burn injury. A small glucose dose is injected through a central venous line, and blood glucose levels are measured before and after the injection. Other measurements, including intra-thoracic blood volume and extra-vascular lung water, will be taken using a specialized device as part of usual care. During the study, patients will be closely monitored with arterial and central venous catheters to collect blood samples at specified times. Researchers will evaluate glucose distribution volume and its relation to fluid balance, lung water, and patient body surface area. They will also study the association between glucose distribution at 24 to 48 hours and patient outcomes. Participation will last through the first four days of intensive care management, with data collected at regular intervals to understand fluid changes and outcomes.
CONDITIONS
Brief Title
Evolution of the Initial Distribution Volume of Glucose in the Severe Burned Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients over 18 years of age
- Patients hospitalized with burns covering at least 30% of body surface area
- Burns caused by a thermal mechanism
- Patients admitted to the CHR Metz-Thionville burn center
- Patients managed within 8 hours post-burn
- Patients affiliated to a social security scheme
- Written consent obtained from patient or authorized representative, or emergency inclusion if consent cannot be obtained
You will not qualify if you...
- Diabetic patients on insulin
- Patients with contraindication to Glucose 30% Proamp solution for injection
- Patients with pre-hospital cardiac arrest
- Patients on extracorporeal circulation (ECMO, ECLS, or CRRT)
- Patients without a central venous line or arterial catheter
- Moribund patients or those with immediate therapeutic limitation
- Patients unable to undergo trans-pulmonary thermodilution monitoring
- Pregnant, parturient, or breastfeeding women
- Patients under guardianship, curatorship, or judicial protection
- Patients with cognitive impairment or language barriers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
screening and enrollment visit
Duration - Up to 96 hours post-burn
Participants receive intravenous glucose injections to measure the initial volume of glucose distribution (IDVG) and undergo haemodynamic monitoring as part of their burn care management.
Multiple assessments on admission, and at 4, 8, 16, 24, 48, 72, and 96 hours post-burn
Trial Site Locations
Total: 1 location
1
CHR Metz-Thionville/Hopital de Mercy
Metz, France, 57085
Actively Recruiting
Research Team
A
Arpiné EL NAR, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here